Status:
COMPLETED
Omega 3 Action on Cardiovascular Risk Factors in Patients Treated With Statins
Lead Sponsor:
Assaf-Harofeh Medical Center
Conditions:
Inflammation
Blood Pressure
Eligibility:
All Genders
30-70 years
Phase:
NA
Brief Summary
Recent evidences showed beneficial effects of omega-3 fatty acids on cardiovascular morbidity and mortality. Regular Omega-3 fatty acid consumption reduces cardiovascular mortality, ischemic heart di...
Detailed Description
Cardiovascular disease is a leading cause of death in the western world. HMG-co A Reductase (statins) stands in the first line of treatment of cardiovascular disease because of their direct effect on ...
Eligibility Criteria
Inclusion
- dyslipidemia controlled (LDL \< 130)
- statin treatment
- triglycerides \< 200
- informed consent
Exclusion
- thrombocytopenia or bleeding tendency
- uncontrolled diabetes mellitus
- uncontrolled hypertension (systolic \> 160 or diastolic \> 100)
- omega 3 pretreatment
- recent acute coronary syndrome or cerebrovascular event (less than 3 months)
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00976872
Start Date
January 1 2008
End Date
December 1 2008
Last Update
June 8 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.